ClinicalTrials.gg
RecruitingNCT04050696Updated Aug 22, 2023

The Use of Electromagnetic Field (EMF) Treatment in Chronic Spinal Cord Injury (SCI) Patients

An interventional study of BQ 1.2 in Incomplete Spinal Cord Injury, sponsored by BrainQ Technologies Ltd.. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-22.

Sponsored by BrainQ Technologies Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Sep 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Paraplegia with a site in United States — 17 open to participants now, 18 under way, 2 of them phase 3. Paraplegia · United States.

Planned enrollment
46th of 54
8 · median 22
Started
2019
with 2 others
No phase
37 of 64
10 open now
Primary completion
2023-12
later than 0 of 17 live
Registered
34th of 64
by date

Among the 64 studies in Paraplegia with a site in United States, this one is the 46th largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2019, is one of 37 with no phase, reaches primary completion later than 0 of the 17 other live ones, and was the 34th registered.

Paraplegia

152 studies on the registry are indexed under Paraplegia; 37 are open to participants now.

Browse Paraplegia studies →

Open to participants now

17 of the 64 studies in Paraplegia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 32 Paraplegia studies recruiting now, 15 (47%) set no upper age limit and 14 (44%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Paraplegia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to further establish safety and efficacy of the BQ EMF treatment of chronic SCI subjects who demonstrate stability in The Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) strength score following a one-month physical therapy run-in period.

Read the detailed description

BQ is a brain-computer interface (BCI) based medical device that produces and delivers non-invasive, low intensity and low frequency electromagnetic fields targeting a patient's central nervous system (CNS) for motor rehabilitation. The technology behind the device utilizes machine learning (ML) tools to identify high-resolution spectral patterns, which characterize motor functions within EEG and MEG/EMG measurements taken during functional motor tasks. These patterns are then translated into a frequency-dependent, low intensity and non-invasive electromagnetic treatment, which applies similar patterns directly to a patient's CNS.

BQ treatment is intended to improve upper limb motor function of chronic SCI patients, over 18 years of age with an incomplete injury and upper limb motor impairment (AIS B - D, Cervical C1 - C8). The treatment will be administered as an adjunctive treatment along with a typical pharmacological and/or non-pharmacological treatment plan.

Study is a prospective, single arm, multicenter study with physical therapy (PT) run-in phase, where each subject serves as his/her own control. Study population will include at least 8 individuals with traumatic or (incident-related) non-traumatic chronic cervical incomplete SCI (AIS B-D) who are 12 - 30 months post-injury, with score between 5 - 35 on GRASSP strength subscore on at least one side, and medically stable.

The primary objective of this study is to evaluate the efficacy of the BQ system treatment in improving upper limb motor function of chronic SCI subjects, compared to their own baseline after stability has been demonstrated during physical therapy run-in period, as measured by improvement in GRASSP strength subscore. An additional secondary objective of the study is to evaluate the efficacy of the BQ system treatment in improving motor recovery, spasticity, pain, QOL, and imaging outcomes in the stated population.

03

Conditions studied

  • Incomplete Spinal Cord Injury

Keywords

  • chronic SCI
  • incomplete SCI
  • central cord syndrome
  • electromagnetic field
  • physical therapy
  • cervical SCI
  • paraplegia
  • tetraplegia
  • upper limb impairment
  • GRASSP
  • ISNCSCI
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and non-pregnant females who are between 18 to 75 years of age
  2. Diagnosed with traumatic or (incident-related) non-traumatic chronic cervical incomplete SCI (AIS B-D), 12 to 30 months from event.
  3. Individuals with a score between 5 - 35 on the GRASSP strength subscore on at least one side
  4. Medically stable
  5. Cognitive status and ability to communicate must be at a level consistent with that which is required to participate in motor rehabilitation regimen (e.g. can follow directions and cued tasks)
  6. Stable pharmacological treatment plan without any planned modifications
  7. Able to engage in physical therapy program as stipulated per protocol
  8. Passive shoulder flexion of at least 60 degrees and passive shoulder abduction of at least 40 degrees, to ensure ability to perform upper limb motor tasks
  9. Negative pregnancy test in women of
  10. Subject can independently provide consent (written or verbal in the presence of a family member) to participate in the study and is willing to comply with study procedures

Exclusion criteria

Exclusion Criteria:

Subjects not eligible for this study include those that have any of the following:

  1. Excessive pain in the UE that limits the administration of the evaluation measurements
  2. Excessive spasticity: subjects with MAS of wrist ≥ 2, or MAS of elbow ≥ 3
  3. Received botulinum toxin in the previous 4 months, or planning of an upcoming injection during the trial period
  4. Participating in any other experimental rehabilitation or drug studies
  5. Medical conditions or circumstances that, in the opinion of the investigators, would preclude safe and/or effective participation
  6. Severe cognitive or psychiatric problems that might significantly impact the successful study conduct
  7. History of epileptic seizures or epilepsy
  8. Implanted electronic medical devices
  9. Alcoholism or drug addiction as defined by within last 5 years
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Treatment (with PT run-in)

    Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period

    Device: BQ 1.2

Interventions

  • DeviceBQ 1.2

    BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen

06

What researchers measure

Primary outcomes

  1. Change from baseline of treatment to end of treatment in the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP - strength subscore):

    The GRASSP is a clinical measure of upper limb impairment, which incorporates the construct of upper limb sensorimotor function. This measurement captures information on upper limb sensorimotor impairment for individuals with tetraplegia and defines neurological status with numerical values, which represent the deficits in a predictive pattern. The GRASSP demonstrates reliability, construct validity, and concurrent validity for use as a standardized upper limb impairment measure for individuals with incomplete SCI (Kalsi-Ryan et al., 2012). Scores can be used to determine relationships between impairment and functional capability of the upper limb. The evaluation includes three domains of hand function: 1. Strength (primary) 2. Sensibility (secondary) 3. Prehension (secondary) For the primary outcome measure, only the strength subscore will be assessed as follows: ● Strength (10 muscles of arm \& hand): motor grade 0-5 for each (sum = subtest total, 0-50)

    Time frame: Week 22

Secondary outcomes

  1. GRASSP (strength subscores)

    The GRASSP is a clinical measure of upper limb impairment, which incorporates the construct of upper limb sensorimotor function. This measurement captures information on upper limb sensorimotor impairment for individuals with tetraplegia and defines neurological status with numerical values, which represent the deficits in a predictive pattern. The GRASSP demonstrates reliability, construct validity, and concurrent validity for use as a standardized upper limb impairment measure for individuals with incomplete SCI (Kalsi-Ryan et al., 2012). Scores can be used to determine relationships between impairment and functional capability of the upper limb. ● Strength (10 muscles of arm \& hand): motor grade 0-5 for each (sum = subtest total, 0-50)

    Time frame: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  2. GRASSP (sensibility and prehension subscores)

    For the secondary outcome measure, the sensibility and prehension subscores will be assessed as follows: * Dorsal sensation (3 locations): each scored 0-4 (sum = subtest score, 0-12) * Palmar sensation (3 locations): each scored 0-4 (sum = subtest score, 0-12) * Prehension ability: 3 grasps (cylindrical, lateral key, tip to tip), each scored 0-4 (sum = 0-12). * Prehension performance: 6 prehension tasks - pour water from bottle, pick up an object, transfer 9 pegs from board to board, screw four nuts onto bolts, each scored 0-5 (sum = subtest score, 0-30).

    Time frame: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  3. ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury)

    This is a system of tests used to define and describe the extent and severity of a subject's spinal cord injury. The subject's grade is based on how much sensation he or she can feel at multiple points on the body, as well as tests of motor function. For the purposes of this study, only the motor subtests and functions (UEMS \& LEMS) will be considered as a secondary outcome measure. The full ISNCSCI will be administered and assessed at baseline and end of treatment only for AIS classification purposes.

    Time frame: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  4. Modified Ashworth Scale (MAS)

    The Modified Ashworth scale (MAS) measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity (Bohannon \& Smith, 1987). Scoring are as follows: * 0: No increase in muscle tone * 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension * 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM * 2: More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved * 3: Considerable increase in muscle tone, passive movement difficult * 4: Affected part(s) rigid in flexion or extension

    Time frame: Week -1, week 1, week 5, week 22

  5. Spinal Cord Independence Measure III (SCIM III - self-care sub-score)

    The Spinal Cord Independence Measure (SCIM) is a disability profile containing 3 sub-scales developed specifically for people with spinal cord injury (SCI). Through measures across its distinct scales, the profile describes subjects' ability to undertake activities of daily living (Ackerman, Morrison, McDowell, \& Vazquez, 2010). Each area is scored according to its proportional weight in these subjects' general activity. The final score ranges from 0 to 100 (Ackerman et al., 2010). The SCIM includes the following areas of function: * Self-care (sub-score 0 - 20) * Respiration and sphincter management (sub-score 0 - 40) * Mobility (sub-score 0 - 40)

    Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  6. Questionnaire of von Korff et al. Grading the Severity of Chronic Pain

    This is a simple method of grading the severity of chronic pain. This questionnaire grades the severity of chronic pain based on its characteristics and its impact on a person's activities (Von Korff, Ormel, Keefe, \& Dworkin, 1992). Answers are graded on a 0 (no) - 10 (extreme) scale for each of the following questions: * Rate pain at present time * Rate of most intense pain in the last 6 months * Rate of average pain in the last 6 months * In the past 6 months, how has pain interfered with your daily activities * In the past 6 months, how has pain interfered with your recreational social and family activities * In the past 6 months, how has pain interfered with your ability to work

    Time frame: Week 1, week 5, week 22

  7. Capabilities of the Upper Extremity Test (CUE-T)

    A 32-item questionnaire with items in seven domains. The CUE test displays excellent test/retest reliability, and excellent correlation with impairment and capacity measures in persons with incomplete SCI. Subjects are scored on a 7-point scale representing self-perceived difficulty: 1 indicating totally limited, can't do at all, and 7 indicating not at all limited. Minimum score is 32 and maximum score is 124 (Marino, Shea, \& Stineman, 1998). Subjects will be asked to complete the following tasks: * 15 unilateral (left and right) items * 2 bilateral items * 3 reaching items * 4 pulling/pushing items * 2 wrist items * 6 hand/finger items * 2 bilateral items

    Time frame: Week 1, week 5, week 22

  8. The Spinal Cord Injury-Quality of Life (SCI-QOL)

    The measurement system was developed to address the shortage and non-uniformity of subject-reported outcome measures for clinical care and research in SCI rehabilitation. It consists of 19 items, measuring emotional health (depression, anxiety, resilience, positive affect and well-being, grief/loss, self-esteem, stigma, psychological trauma); physical-medical health (bowel management, bladder management, bladder complications, pressure ulcers, pain interference, pain behavior); social participation (ability to participate in social roles and activities, satisfaction with social roles and activities, independence); physical function (basic mobility, self-care, fine motor functioning, wheelchair mobility, ambulation) (Tulsky et al., 2015).

    Time frame: Week 1, week 5, week 22

  9. Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI) scans

    For applicable subjects, MRI scans will be performed, preferably with a 3.0 T Ingenia Philips scanner, according to the follow sequences: A. Sagittal T2 B. Sagittal STIR C. Sagittal PW (proton density) D. Sagittal T1 E. Sagittal DTI F. Axial T1 G. Axial T2 MRI results will be analyzed to quantify tissue integrity (e.g. white matter, grey matter, cerebrospinal fluid). DTI measurements will be used to identify water movement, which, in the CNS, is often localized within axons, and provides high contrast towards white matter, indicating the quality and quantity of nerve fibers. This endpoint is not obligatory per protocol; failure to complete in contraindicated subjects is not considered a protocol deviation per Good Clinical Practice.

    Time frame: Week 5, week 22

Other outcomes

  1. Surface EEG

    Surface EEG will be recorded throughout the trial to gauge subject progress. This endpoint is exploratory, and will not be used for diagnostic or inclusionary/exclusionary purposes.

    Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26

  2. Surface EMG

    Surface EMG will be recorded throughout the trial to gauge subject progress. EMG will be recorded in a bipolar setting from electrode pairs on the following muscles: flexor carpi radialis brevis, extensor carpi radialis brevis, flexor carpi ulnaris, extensor carpi ulnaris. The subjects will be seated and requested to perform hand and arm movements, to their best ability, upon cues. This endpoint is exploratory, and will not be used for diagnostic or inclusionary/exclusionary purposes.

    Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26

  3. Smoothness of reaching movement

    Upper extremity (UE) kinematics data will be collected using a motion capture system. Retro-reflective markers will be attached directly to the subject with use of double sided tape on the anatomical joint mark points using the modified Helen Hayes marker set (torso, head and upper extremity). All kinematic data will be collected and time matched with the EMG data and transferred to a custom MATLAB (Mathworks, Natick, MA) algorithm code for further analysis. Upper extremity joint kinematics, muscle activation (sEMG) and EEG data will be recorded during several activities. To evaluate the smoothness of movements, the third derivative of the UE joint angles will be computed and considered for estimation of smoothness at the shoulder, elbow and wrist joints.

    Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  4. Range of motion (ROM)

    Upper extremity (UE) ROM (in the sagittal, frontal, and transverse planes) will be collected using a motion capture system. Retro-reflective markers will be attached directly to the subject with use of double sided tape on the anatomical joint mark points using the modified Helen Hayes marker set (torso, head and upper extremity). Upper extremity ROM, muscle activation (sEMG) and EEG data will be recorded during several activities.

    Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34

  5. Venous blood collection

    Five ml whole venous blood will be collected at baseline (W5), midterm (W14), at end of treatment phase (W22), and first follow-up (W26) from all subjects. Blood will be separated to two test tubes, 2.5 CC in each, one with anti-coagulant (EDTA) and one without. Red blood cells will be separated from plasma (EDTA tube, by centrifugation) or from serum by clotting. Plasma and serum samples will be frozen in 0.5 cc aliquots at -80°C. Samples will be analyzed for CNS insult biomarkers, including glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), as well as brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and nerve growth factor beta (NGFβ). This draw is an exploratory endpoint, and is not obligatory PP if contraindicated.

    Time frame: Week 1, week 5, week 22

  6. Assessment of device's Usability by user (Human factors and usability analysis)

    Usability form to be completed by device user (operator) shall include: 1. Subjective feedback questionnaire: Subjective feedback focusing on any concerns on using device, ease of use, and potential deviations from proper use. 2. Informative questions to ensure proper understanding and operation of the device. The form is designed in order to track possible deviations from required treatment due to human factors, as well as specific elements of the treatment which may pose a risk due to human factors and have not been accounted for in the design and validation process.

    Time frame: Week 0 of 1st patient, week 22 of 2nd patient, week 34 of 4th patient

  7. Rate of deviation of device user from expected input sequence (Human factors and usability analysis)

    Deviation of device user from expected input sequence, defined as exiting the "treatment flow" during treatment or canceling treatment unnecessarily, and obtained by user activity logging. The expectation is that these deviations should occur in less than 10% of treatment sessions

    Time frame: Week 34 of 4th patient

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Metadata can be made available, upon reasonable request Individual patient data (IPD) to be shared if significant need/benefit can be demonstrated, and only with permission of individual subject, as it is not specifically covered in informed consent form (ICF)

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2019 (actual). Primary completion is estimated for Dec 2023, 50 months after the start.

Of 60 interventional studies with no phase under Paraplegia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 131. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2019
First posted
Aug 8, 2019
StartActual
Sep 18, 2019
Primary completionEst.
Dec 1, 2023
CompletionEst.
Feb 1, 2024
Last update
Aug 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04050696
Lead sponsor
BrainQ Technologies Ltd.
Collaborators
The Miami Project to Cure Paralysis, Sheba Medical Center, Kessler Institute for Rehabilitation
Responsible party
Sponsor
First posted
Aug 8, 2019
Start date
Sep 18, 2019
Primary completion
Dec 1, 2023 (estimated)
Completion
Feb 1, 2024 (estimated)
Last update
Aug 22, 2023

Study contacts

Assaf Lifshitz
Contact
assaf@brainqtech.com
+972-54-4586787
Gabi Zeilig, Ph.D.
principal investigator · Sheba Medical Center
Dalton Dietrich, Ph.D.
principal investigator · The Miami Project to Cure Paralysis
Ghaith Androwis, Ph.D.
principal investigator · Kessler Institute of Rehabilitation

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion